MOUNTAIN VIEW, CA--(Marketwired - July 10, 2013) - Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that Will K. Weinstein has been appointed as a Director, effective as of July 8, 2013. The appointment increases the Company's board membership to eight, seven of whom are independent. Mr. Weinstein brings to the board over 40 years of experience in the financial services industry.
"Will's extensive financial services expertise will be extremely valuable for us as our EP and vascular businesses continue to grow," said Mike Eagle, Chairman of the Board for Hansen Medical. "We look forward to leveraging his vast finance experience."
Currently, Mr. Weinstein serves as a Financial and Investment Advisor and Money Manager to a number of individuals and corporations active in the equity markets. He is also a limited partner of Conifer Securities in San Francisco. Mr. Weinstein was a Governor of the Midwest Stock Exchange for five years, and also served for five years as a Governor of the American Stock Exchange until its merger with NASDAQ in 1998. Mr. Weinstein was Chairman and CEO of Genesis Merchant Group Securities in San Francisco from 1989 until it was sold in 1997. He then started and managed a hedge fund and two private equity partnerships. Prior to Genesis, he was the Investment and Financial Policy Advisor to the Pritzker family in Chicago. Previously, Mr. Weinstein was the Managing Partner of Montgomery Securities in San Francisco and Chairman of its Investment Policy Committee. He was also a member of the Executive Committee of Oppenheimer and Co. and its partner in charge of trading in the 1970's.
Mr. Weinstein is a member of the board of the Osher Center for Integrative Medicine in San Francisco, and he recently joined the board of the San Francisco State University Foundation, where he is a member of the endowment committee. Mr. Weinstein's previous board affiliations include DHL Incorporated, Butterfield & Butterfield, Beverly Enterprises, Mt. Zion Hospital, the San Francisco Chapter of the Juvenile Diabetes Research Foundation, the San Francisco Performances, the Robert H. Lurie Comprehensive Cancer Center, the UCSF Department of Prostate Cancer Advocacy Core and the City College of San Francisco Foundation. He was a member of a former California Controller's Advisory Council for Investment and served as the West Coast Chair for Bridging the Rift Foundation.
Over the past several years, Mr. Weinstein has taught at many universities throughout the United States and abroad. This summer will be his tenth teaching "Integrity and Ethics in the Real World" at the University of Hawaii at Manoa, a class co-sponsored by the Richardson School of Law and the Shidler College of Business. In addition, Mr. Weinstein had taught "Ethics in Decision Making" at the Graduate Business School at San Francisco State University since 2006; before taking a leave over the last two years. Prior to his duties at San Francisco State University, he co-taught a business ethics class at San Francisco City College with the Dean of the Business School.
"Hansen Medical is at the forefront of innovation in intravascular robotics," said Mr. Weinstein. "I am pleased to be joining the Company at such an exciting time."
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is a global leader in intravascular robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, NorthStar™ Robotic Catheter and related accessories, which are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices, have undergone both CE marking and 510(k) clearance and are commercially available in the European Union, and the U.S. In the European Union, the Company's Sensei® X Robotic Catheter System and Artisan Control Catheter are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the U.S. the Company's Sensei X Robotic Catheter System and Artisan Control Catheter were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X System and Artisan Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established. Additional information can be found at www.hansenmedical.com.
This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, objectives, milestones and future events. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements about the anticipated growth in Hansen Medical intravascular robotics technology for EP and vascular applications. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; the commercial viability of our products in the electrophysiology and vascular markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of economic conditions on capital spending by our potential customers; the uncertain timelines for the sales cycle for newly introduced products; the rate of adoption of our systems and the rate of use of our catheters; the scope and validity of intellectual property rights applicable to our products; competition from other companies; our ability to recruit and retain key personnel; our ability to maintain our remedial actions over previously reported material weaknesses in internal controls over financial reporting; our ability to manage expenses and cash flow, and obtain additional financing; and other risks more fully described in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 filed with the SEC on May 10, 2013 and the risks discussed in our other reports filed with the SEC. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart Design), Sensei and Lynx are registered trademarks, and Magellan and NorthStar are trademarks of Hansen Medical, Inc. in the United States and other countries.